Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma

被引：33
作者：
Kindler, HL [1 ]
机构：
[1] Univ Chicago, Med Ctr, Dept Hematol Oncol, Chicago, IL 60637 USA
来源：
LUNG CANCER | 2004年 / 45卷
关键词：
novel cytostatic agents; vascular endothetial; growth factor; epidermal growth factor; platelet derived growth factor; tyrosine kinase;
D O I：
10.1016/j.lungcan.2004.04.022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
It is now known that vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) are autocrine growth factors in malignant mesothelioma; epidermal growth factor receptor (EGFR) is also highly overexpressed. Cytotoxic drugs that target these growth factors offer fresh potential for the treatment of mesothelioma. Clinical trials have recently been initiated to evaluate the anti-tumour activity of the VEGF inhibitors SU5416, bevacizumab and thalidomide. ZD1839 (Iressa, AstraZeneca), an inhibitor of EGFR tyrosine kinase, is also being evaluated. Two clinical trials are planned to evaluate the two PDGF inhibitors Gleevec (Imatinib mesylate, STI-571, Novartis Pharmaceuticals) and PTK787 (Novartis Pharmaceuticals). (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：S125 / S127
页数：3
相关论文
共 19 条
  • [1] Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
  • [2] Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
  • [3] DORAI T, 1994, MOL PHARMACOL, V46, P437
  • [4] Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
    Eisen, T
    Boshoff, C
    Mak, I
    Sapunar, F
    Vaughan, MM
    Pyle, L
    Johnston, SRD
    Ahern, R
    Smith, IE
    Gore, ME
    [J]. BRITISH JOURNAL OF CANCER, 2000, 82 (04) : 812 - 817
  • [5] GERWIN BI, 1987, CANCER RES, V47, P6180
  • [6] GOVINDAN R, 2001, P AN M AM SOC CLIN, V20, P339
  • [7] Kabbinavar F. F., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P488
  • [8] Malignant pleural mesothelioma
    Kindler H.L.
    [J]. Current Treatment Options in Oncology, 2000, 1 (4) : 313 - 326
  • [9] KINDLER HL, 2001, CURR CLIN TRIALS THO, V4, P2
  • [10] Langerak AW, 1996, J PATHOL, V178, P151
12